Concepedia

Chang Han

CH

29

Publications

7.7K

Citations

22

H-Index

1997

Active since

Affiliations

Tulane University(Current)

Bristol-Myers Squibb (United States)

Memorial Sloan Kettering Cancer Center

Huazhong University of Science and Technology

Chungnam National University

Chang Han is an author at Tulane University specializing in medicine, pathology, and tumor biology.

ORCID

Top concepts

Publications per year

1997–2023

29

Publications

29

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański et al. · New England Journal of Medicine · 2018 · 3.1K citations · Full text

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt et al. · Cancer Discovery · 2018 · 1.5K citations · Full text

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Matthew D. Hellmann, Margaret K. Callahan, Mark M. Awad et al. · Cancer Cell · 2018 · 882 citations · Full text

, , +9

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Neal Ready, Matthew D. Hellmann, Mark M. Awad et al. · Journal of Clinical Oncology · 2019 · 584 citations · Full text

Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors

Nathan O. Siemers, James L. Holloway, Chang Han et al. · PLoS ONE · 2017 · 203 citations · Full text

, , +20

Rows per page

1–5 of 29